Histopathologic Features in Relation to Pretreatment Tumor Growth in Patients with Glioblastoma.

BACKGROUND Rapid growth is a well-known property of glioblastoma (GBM); however, growth rates vary among patients. Mechanisms behind such variation have not been widely studied in human patients. We sought to investigate relationships between histopathologic features and tumor growth estimated from pretreatment magnetic resonance imaging scans. METHODS In 106 patients with GBM, 2 preoperative T1-weighted magnetic resonance imaging scans obtained at least 14 days apart were segmented to assess tumor growth. A fitted Gompertzian growth curve based on the segmented volumes divided the tumors into 2 groups: faster and slower growth than expected based on the initial tumor volume. Histopathologic features were investigated for associations with these groups, using univariable and multivariable logistic regression analyses. RESULTS The presence of high cellular density and thromboses was significantly associated with radiologic growth in the multivariable analysis (P = 0.018 and 0.019, respectively), with respective odds ratios of 3.0 (95% confidence interval, 1.2-7.4) and 4.3 (95% confidence interval, 1.3-14.5) for faster growing tumors. CONCLUSIONS Our findings show that high cellular density and thromboses are significant independent predictors of faster growth in human GBM. This finding underlines the importance of hypercellularity as a criterion in glioma grading. Furthermore, our findings are concordant with hypotheses suggesting hypoxia triggered by thromboses to be relevant for growth of GBM.

[1]  Gargi Chakraborty,et al.  Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. , 2009, Cancer research.

[2]  Paul Thompson,et al.  Mapping tumor growth rates in patients with malignant gliomas: A test of two algorithms , 2000, NeuroImage.

[3]  K. Tsuboi,et al.  Regrowth patterns of supratentorial gliomas: estimation from computed tomographic scans. , 1986, Neurosurgery.

[4]  Ole Solheim,et al.  Growth dynamics of untreated glioblastomas in vivo. , 2015, Neuro-oncology.

[5]  Daniel J Brat,et al.  Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma , 2004, Laboratory Investigation.

[6]  G. Semenza,et al.  Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .

[7]  Jiri Zavadil,et al.  Knock down of HIF-1α in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres , 2010, Molecular Cancer.

[8]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[9]  S. Torp,et al.  The Histopathological Spectrum of Primary Human Glioblastomas with Relations to Tumour Biology , 2012 .

[10]  B A Kall,et al.  Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. , 1987, Journal of neurosurgery.

[11]  B. Kálmán,et al.  Molecular Heterogeneity of Glioblastoma and its Clinical Relevance , 2014, Pathology & Oncology Research.

[12]  D. Scheie,et al.  Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme , 2010, Acta neurologica Scandinavica.

[13]  J. Murray,et al.  Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion , 2003, Journal of the Neurological Sciences.

[14]  Rolf Bjerkvig,et al.  In vivo models of primary brain tumors: pitfalls and perspectives , 2012, Neuro-oncology.

[15]  D. Brat,et al.  Diagnosis of malignant glioma: role of neuropathology , 2008, Journal of Neuro-Oncology.

[16]  B. Scheithauer,et al.  Cellular proliferation in pilocytic and diffuse astrocytomas. , 1999, Journal of neuropathology and experimental neurology.

[17]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[18]  T. Taxt,et al.  Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma , 2011, Proceedings of the National Academy of Sciences.

[19]  W Ellis,et al.  The influence of volumetric tumor doubling time, DNA ploidy, and histologic grade on the survival of patients with intracranial astrocytomas. , 1995, AJNR. American journal of neuroradiology.

[20]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[21]  D. Ross,et al.  A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. , 1997, Journal of neuropathology and experimental neurology.

[22]  Laird Ak DYNAMICS OF TUMOR GROWTH. , 1964 .

[23]  S. Raab,et al.  Interobserver variability associated with the MIB‐1 labeling index , 2001, Cancer.

[24]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Wardlaw,et al.  A pilot study of brain tumour growth between radiotherapy planning and delivery. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[26]  D. Louis WHO classification of tumours of the central nervous system , 2007 .

[27]  T. Cloughesy,et al.  Contrast‐enhancing tumor growth dynamics of preoperative, treatment‐naive human glioblastoma , 2016, Cancer.

[28]  Albert Lai,et al.  Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. , 2009, Cancer research.

[29]  H. Wakimoto,et al.  Prognostic significance of Ki‐67 labeling indices obtained using MIB‐1 monoclonal antibody in patients with supratentorial astrocytomas , 1996, Cancer.

[30]  G. Reifenberger,et al.  Molecular neuro-oncology in clinical practice: a new horizon. , 2013, The Lancet. Oncology.

[31]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[32]  F. Gaillard,et al.  MRI Grading versus Histology: Predicting Survival of World Health Organization Grade II–IV Astrocytomas , 2015, American Journal of Neuroradiology.

[33]  P. Wen,et al.  Response Assessment in Neuro-Oncology , 2011, Current oncology reports.

[34]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[35]  R. Bourgon,et al.  Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  B. Su,et al.  Tissue factor expression and angiogenesis in human glioma. , 2002, Clinical biochemistry.

[37]  Anne Line Stensjøen,et al.  Does Pretreatment Tumor Growth Hold Prognostic Information for Patients with Glioblastoma? , 2017, World neurosurgery.

[38]  D. Brat,et al.  RESEARCH ARTICLE: Intravascular Thrombosis in Central Nervous System Malignancies: A Potential Role in Astrocytoma Progression to Glioblastoma , 2007, Brain pathology.

[39]  M. J. van den Bent,et al.  Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? , 2011, The Lancet. Oncology.

[40]  T. Bathen,et al.  Differentiating diffuse World Health Organization grade II and IV astrocytomas with ex vivo magnetic resonance spectroscopy. , 2013, Neurosurgery.

[41]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[42]  Akio Asai,et al.  Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging , 2010, Brain Tumor Pathology.

[43]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  D. Zagzag,et al.  Angiogenesis in Gliomas: Biology and Molecular Pathophysiology , 2005, Brain pathology.

[45]  David N Louis,et al.  Molecular pathology of malignant gliomas. , 2006, Annual review of pathology.

[46]  R. Prayson,et al.  Role of MIB1 in Predicting Survival in Patients with Glioblastomas , 2005, Journal of Neuro-Oncology.

[47]  R. Prayson Cell Proliferation and Tumors of the Central Nervous System Part 1: Evaluation of Mitotic Activity , 2002, Journal of neuropathology and experimental neurology.

[48]  T. Kuwabara,et al.  Estimation of rate of growth of malignant brain tumors by computed tomography scanning. , 1983, Surgical neurology.

[49]  J. Kuratsu,et al.  Expression of tissue factor correlates with grade of malignancy in human glioma , 1996, Cancer.

[50]  Daniel J Brat,et al.  'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis , 2006, Journal of neuropathology and experimental neurology.